Seeking Alpha

Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and ...

PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic ® (semaglutide) injection 1 ...
KXAN

ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis ...
MarketWatch

Ozempic(R) (semaglutide) injection 1 mg showed -2-

1. Bonaca M, Catarig AM, Houlind K, et al. The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People with Type 2 Diabetes and Peripheral Artery Disease: Primary Results ...
Pharmabiz

Novo Nordisk files sNDA of semaglutide injection 7.2 mg with US FDA for approval to treat obesity

Novo Nordisk, a leading global healthcare company with a heritage of more than 100 years in diabetes care field, has announced the submission of an sNDA to the US Food and Drug Administration (FDA) ...
Medindia

FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy® pill, the first oral GLP-1 medicine for obesity in the US.3 Wegovy® pill is used with a ...